Europe Leukemia Therapeutics market has been estimated at USD 1.81 Billion in 2019 and is projected to reach USD 2.71 Billion by 2024, at a CAGR of 8.4% during the forecast period from 2019 to 2024.
Leukemia is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.
The market for Leukemia Therapeutics in Europe is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and a growing number of biotechnology firms.
But due to factors like the high cost of drugs and treatments along with a large number of entry-to-market barriers, the market growth is feared to diminish.
This research report segmented and sub-segmented into the following categories:
By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.
Europe holds the second-largest share in the global market. A number of factors such as growing awareness of leukemia screening programs and government support are paving the way for companies to penetrate into the European Leukemia Therapeutics market.
Key players operating in the Europe Leukemia Therapeutics market profiled in this report are Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Condition
5.1.1 Chronic Lymphatic Leukemia
5.1.2 Acute Lymphatic Leukemia
5.1.3 Chronic Myeloid Leukemia
5.1.4 Acute Myeloid Leukemia
5.2 By Diagnosis
5.2.1 CT scan
5.2.2 Biopsy
5.2.3 MRI
5.3 By Treatments
5.3.1 Chemotherapy
5.3.2 Radiation therapy
5.3.3 Immunotherapy
5.3.4 Surgery
5.3.5 Targeted Therapy
5.3.6 Bone marrow transplant
5.3.7 Stem Cell Therapy
5.4 By Drugs
5.4.1 Gleevec
5.4.2 Sapacitabine
5.4.3 GA101
5.4.4 Vasaroxine
5.4.5 Tosedosat
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 GlaxoSmithKline Pharmaceuticals Limited
9.3 Novartis International AG
9.4 Bristol-Myers Squibb
9.5 Eisai Co. Ltd
9.6 Biogen Idec
9.7 ERYtech Pharma
9.8 Celgene Corporation
9.9 Genmab A/S
9.10 Cephalon Inc.
9.11 Clavis Pharma
9.12 Pfizer Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
